We are open to work under different business models including:
- In-licensing
- Co-marketing
- Co-promotion
- Distribution
- Local representation of international companies
Some of our collaborations include
| COMPANY |
COUNTRY |
SINCE |
PRODUCT (API) |
| Biocon |
IN |
2024 |
Abevmy ® (bevacizumab)
Fulphila ® (Pegfilgrastin) |
| Mylan/Viatris |
UK |
2024 |
Azacitidine
Lenalidomide
Fulvestrant
Abiraterone |
| Axunio Pharma GmbH |
DE |
2023 |
Pirfenidone Axunio® (pirfenidone) |
| Bionorica |
DE |
2022 |
Sinupret® extract (Gentiana lutea L., Primula veris L., Rumex crispus L., Sambucus nigra L., Verbena officinalis L.)
Canephron® Uno (Centaurium erythraea Rafn s.l., herba, Levisticum officinale Koch., radix, Rosmarinus officinalis L., folium)
Imupret® (Althaeae radix, Quercus cortex, Matricariae flos, Taraxaci herba, Equiseti herba, Millefolii herba, Juglandis folium) |
| Servier |
FR |
2018 |
Prestalia® (perindopril + amlodipine) |
| Ιnfectopharm |
DE |
2016 |
Fomicyt® (fosfomycin sodium) |
| Takeda |
CH |
2015 |
Vipidia® (alogliptin)
Vipdomet® (alogliptin + metformin)
Incresync® (alogliptin + pioglitazone) |
| Italfarmaco |
IT |
1990 |
Legofer® (iron proteinsuccinylate) |
ELPEN is always seeking for on/off patent originator or biosimilar products, for which Phase III clinical trials have been completed, and for which FDA or EMA marketing authorization procedures have started or will be starting shortly. We may also assess potential partnerships involving products already authorized and marketed in the Greek market, and last but not least we seek to work with companies that are not currently represented in Greece.
At present ELPEN's portfolio in its domestic markets includes Rx and OTC products from therapeutic areas such as:
- Cardiovascular
- Diabetes
- Respiratory
- Central Nervous System
- Oncology - Hematology
- Immunology
- Infections
- Gastrointestinal
- Musculoskeletal
- HIV
- Rare Diseases
- Women Healthcare
- Urology
To find out more, please contact us at bdgen@elpen.gr